Impact Factor 6.429

The 5th most cited journal in Immunology

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2018.00139

Immune mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors

 Rodolfo A. Kolliker Frers1,  Vanesa Cosentino2, Julia Tau3, Eduardo M. Kerzberg2, Adriana Urdapilleta3, Monica Chiocconi4, Nora Kogan5,  MATILDE OTERO-LOSADA6* and  Francisco Capani1
  • 1Laboratory of Cytoarchitecture and Neuronal Plasticity, Institute of Cardiological Research, School of Medicine, University of Buenos Aires, Argentina
  • 2Unidad de Reumatología, Hospital Ramos Mejía, Argentina
  • 3Departamento de Radiología, Hospital Ramos Mejía, Argentina
  • 4Laboratorio de determinaciones hormonales. Sección de metabolismo de lípidos e hidratos de carbono. División Endocrinología. Departamento de Diagnóstico y Tratamiento., Hospital Ramos Mejía, Argentina
  • 5Sección Psoriasis, División Dermatología. Departamento de Clínica, Hospital Ramos Mejía, Argentina
  • 6Laboratorio de HPLC, Instituto de Investigaciones Cardiológicas. University of Buenos Aires, National Research Council. ININCA.UBA.CONICET., Argentina

Studies on the inflammatory burden in recent-onset psoriatic arthritis (PsA) patients without conventional cardiovascular risk factors (CVRFs) are not available. This preliminary study focuses on cardiovascular risk in cutaneous psoriasis (CPs) and recent-onset PsA patients. Blood biochemistry (glucose, cholesterol, uric acid, lipid profile and apolipoprotein B) was analysed using standard kits. Pro-atherogenic inflammation markers, C-reactive protein (CRP) and interleukin-6 (IL-6), and endothelial activators monocyte chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1), were determined by ELISA. Ultrasound images allowed measuring carotid intima-media thickness (cIMT).
Our study first shows an increase in cIMT, and in serum levels of sICAM-1 and CRP in recent-onset PsA patients not presenting conventional CVRFs over the non-medicated time-period, from disease diagnosis to the beginning of pharmacological treatment, compared with healthy subjects. The outcome highlights the importance of monitoring serum level of sICAM1, CRP, and cIMT, and the value of primary prevention in psoriatic patients even with no history of cardiovascular events.

Keywords: atherogenesis, Atherosclerosis, chronic inflammation, C-Reactive Protein, Cytokines, psoriatic arthritis, CIMT, IL-6, soluble ICAM-1

Received: 23 Aug 2017; Accepted: 16 Jan 2018.

Edited by:

Philippe Saas, INSERM UMR1098 Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, France

Reviewed by:

Dietmar Fuchs, Innsbruck Medical University, Austria
Nandor G. Than MD, PhD, Hungarian Academy of Sciences (MTA), Hungary  

Copyright: © 2018 Kolliker Frers, Cosentino, Tau, Kerzberg, Urdapilleta, Chiocconi, Kogan, OTERO-LOSADA and Capani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. MATILDE OTERO-LOSADA, PHD., Instituto de Investigaciones Cardiológicas. University of Buenos Aires, National Research Council. ININCA.UBA.CONICET., Laboratorio de HPLC, Buenos Aires, 1122, Argentina, molly1063@gmail.com